about
Molecular sequelae of proteasome inhibition in human multiple myeloma cellsMutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma.The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.Molecular sequelae of histone deacetylase inhibition in human malignant B cells.Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.p53 mutations detection in urinary bladder cancer in the Greek population: application of the NIRCA assay.RANKL and OPG mRNA level after non-surgical periodontal treatment.Ductal cells of minor salivary glands in Sjögren's syndrome express LINE-1 ORF2p and APOBEC3B.Evidence for APOBEC3B mRNA and protein expression in oral squamous cell carcinomas.Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation.Expression of MMPs and TIMP-1 in smoker and nonsmoker chronic periodontitis patients before and after periodontal treatment.Atherosclerosis of the carotid artery: absence of evidence for CMV involvement in atheroma formationTargeting BRAFV600E in thyroid carcinoma: therapeutic implicationsThe effect of smoking on the mRNA expression of MMPs and TIMP-1 in untreated chronic periodontitis patients: a cross-sectional studyExpression of receptor activator of NF-κB ligand and osteoprotegerin in peripheral giant cell granulomas of the jawsA comparative study of bone remodeling molecules expression in different types of jaw ameloblastoma
P50
Q34393832-78A10DD0-52EE-473A-B536-F1B46FD797CDQ40005544-ED203C42-C5F7-4C6E-BDB9-D4BBC87F472FQ40258614-DBF1B7CA-D2E0-4CCC-8031-9F2EA793754AQ40356297-80D529B3-6E5F-4A8B-9AA3-A918EABB1B0CQ44211035-1BDFEB7D-E936-450C-B26A-46D154EB799AQ44280918-C7E6AD10-D0B1-4839-AC7B-850B8465F60FQ45205310-C8E28BDB-BF19-445D-BD10-DC93C9FCE1D3Q45230119-3E1F5FD6-AD9B-44FA-BE6C-5D7EA5317B44Q45338047-BA432BF3-1D32-43C6-9D72-A1786244347EQ47618684-E2ADCD36-F915-43AB-AF26-BA38A1393858Q51341803-A72B78E4-CFFA-4372-A201-AE3EFBB9E735Q53617699-D77DD478-EF7F-4C91-87B8-800E1339930BQ54316385-7DFFF68C-FD57-46FF-9C2C-5569C7A27E5BQ74317941-EE244917-C8F0-47E7-A679-68DD3224731BQ79961076-1489857F-6272-4690-9115-14DD7A3656BCQ84511757-74C02791-8C7F-48EE-95C1-78E5EB8636A4Q84720128-5A776599-A491-47D6-8144-6E507644E79BQ85353936-9E378D5C-E25F-4237-81C4-165EB6970934
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Galinos Fanourakis
@ast
Galinos Fanourakis
@en
Galinos Fanourakis
@es
Galinos Fanourakis
@nl
Galinos Fanourakis
@sl
type
label
Galinos Fanourakis
@ast
Galinos Fanourakis
@en
Galinos Fanourakis
@es
Galinos Fanourakis
@nl
Galinos Fanourakis
@sl
prefLabel
Galinos Fanourakis
@ast
Galinos Fanourakis
@en
Galinos Fanourakis
@es
Galinos Fanourakis
@nl
Galinos Fanourakis
@sl
P106
P21
P31
P496
0000-0003-3866-0429